JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

NEWS PROVIDED BY

JanOne Inc. 
28 Jun, 2023

PR NewsWire

LDN therapy a new hope for people suffering from chronic pain?

MedExpress Team
17 August 2023
https://www.medexpress.pl/blogosfera/terapia-ldn-nowa-nadzieja-dla-osob-cierpiacych-na-przewlekly-bol/

The Utilization of Low Dose Naltrexone for Chronic Pain

CNS Drugs
28 July 2023
https://pubmed.ncbi.nlm.nih.gov/37505425/

JanOnes Innovative Approach to Addressing Chronic Pain Filing International Patent Application for Low Dose Naltrexone

Best Stocks
28 June 2023
https://beststocks.com/janones-innovative-approach-to-addressing-chr/

Low Dose Naltrexone's Utility for Non-Cancer Centralized Pain Conditions - A Scoping Review

Pain Med
11 June 2023
https://pubmed.ncbi.nlm.nih.gov/37302106/

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series

J Pain Res
14 June 2023
https://pubmed.ncbi.nlm.nih.gov/37337611/

Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis

Biomedicines
As revised 23 March 2023
https://www.mdpi.com/2227-9059/11/4/1087

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians
22 February 2023
https://www.biospace.com/article/releases/janone-to-present-important-trial-results-at-annual-meeting-of-american-society-of-interventional-pain-physicians/